bpc 157 tb 500 human clinical data BPC-157 vs TB-500: research summary and key differences bpc-157 dosage human clinical data
Description
G., Dambach, L
10.1038/s41392-023-01577-3 112 ReidM.SpenceJ.NwokochaM.PalaciosJ.NwokochaC
[36] Antibodies to intrinsic factor and parietal cells cause the destruction of the oxyntic gastric mucosa, in which the parietal cells are located, leading to the subsequent loss of intrinsic factor synthesis
Convenient Administration: These medications are administered via a simple injection, typically once a week
They are usually only prescribed if the infection is bacterial and symptoms are persistent or severe
